Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05511428 · OUTCOME

Financial Toxicity

Home Based Daratumumab Administration for Patients With Multiple Myeloma · Source last updated 2025-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
scores on a scale (0-44)
Interval / dispersion
Standard Deviation
Time frame
At Visit 3, Day 57

What was measured

Financial toxicity will be measured using the COST survey. FACIT-COST (v2) score (range: 0-44). A lower score indicates higher financial toxicity, while a higher score implies better financial well-being.

Groups in this outcome

Treatment (daratumumab and hyaluronidase-fihj)

Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Daratumumab and Hyaluronidase-fihj: Given SC Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies Interview: Ancillary studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (daratumumab and hyaluronidase-fihj)18

Reported measurements

Source class 1
Values in scores on a scale (0-44) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (daratumumab and hyaluronidase-fihj)24.89.7Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        9.7
        value
        24.8
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Financial toxicity will be measured using the COST survey. FACIT-COST (v2) score (range: 0-44). A lower score indicates higher financial toxicity, while a higher score implies better financial well-being.
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Daratumumab and Hyaluronidase-fihj: Given SC Questionnaire Administration: Ancillary studies Quality-of-Life Assessment: Ancillary studies Interview: Ancillary studies
    id
    OG000
    title
    Treatment (daratumumab and hyaluronidase-fihj)
param Type
MEAN
reporting Status
POSTED
time Frame
At Visit 3, Day 57
title
Financial Toxicity
type
SECONDARY
unit Of Measure
scores on a scale (0-44)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice